Cure for Paranoia Wins 2026 NPR Tiny Desk Contest
The band took the top prize in NPR's annual competition. NPR's Ailsa Chang interviewed Cameron McCloud of Cure for Paranoia on All Things Considered. The segment aired May 12, 2026.
ww2.kqed.orgCure for Paranoia won the 2026 Tiny Desk Contest, NPR reported. NPR's Ailsa Chang spoke with Cameron McCloud of Cure for Paranoia about what it took to win this year's contest. The conversation aired on All Things Considered.
The segment aired on May 12, 2026 at 5:20 PM ET. It ran for exactly 8:00. The byline lists Tinbete Ermyas, Kai McNamee, Elle Mannion, and Ailsa Chang. NPR produced the audio player embed that accompanied the story online.
“Cure for Paranoia shares what it took to win this year's Tiny Desk Contest." — NPR The 2026 Tiny Desk Contest winner earned national airtime on the same day the results were announced. Listeners could toggle options to download or embed the 8-minute conversation.”
Transparency
Reported by a single outlet. This score reflects source tier and factual specificity — corroboration is limited with one source.
Story details
Related Stories
thehindu.comU.S. Strikes Botswana-Flagged Tanker in International Waters; Iran Blockade in Effect
A U.S. aircraft fired an AGM-114 Hellfire missile into the engine room of the M/T Lexie on Tuesday, disabling the unladen vessel as it headed toward Kharg Island. The strike followed repeated ignored warnings over 24 hours.
news.sky.comFed Chairman Names Two Outside Advisers During Transition
Federal Reserve Chairman Kevin Warsh appointed two interim advisers shortly after taking the post. One previously contributed to a conservative plan calling for major changes at the central bank.
observer.comForte Biosciences Accepts Resignation of Director David Veitch
Forte Biosciences disclosed the resignation of independent director David Veitch from its board effective June 1 2026. The departure reduces the company's board size and triggers standard SEC and Nasdaq disclosure obligations for director changes at the clinical-stage biopharmace…